Rusan Pharma unveils ₹300 crore API manufacturing plant in MP’s Pithampur

A piece of news is taking place regarding Rusan Pharma investing 300 Crores in the New API Facility in  MP’s Pithampur. This news is getting circulated on the web and people are trying to collect each and every detail about the news. A pharmaceutical company, Rusan Pharma released a new active pharmaceutical ingredient facility. This launching happened on the day of Saturday in Pithampur, Madhya Pradesh. This news is getting circulated on the web and gaining people attention of the people. What happened? What is the entire matter behind the launch? We will discuss everything in this article. Let’s continue the article.

 New API Facility in MP's Pithampur

Rusan Pharma unveils ₹300 crore API manufacturing plant

According to the report, this facility is ready to make 400 metric of APIs annually and is expected to make over 300 jobs. The organization has made an investment of Rs 300 crore in the facility, which is situated within the Pithampur Special Economic Zone. The new provision will argue Rusan  Pharma’s existing API capacity, motiving to give critical APIs to face face-off the rising demand for its treatment of addiction and pain management products in India and universally. We will tell you more important details about the news, which you will find in the next section of the article.

Rusan Pharma Invests 300 Crores

On the basis of the report, The organization is famous for increasingly inventive products, such as Buprenorphine Sublingual and Buprenorphine Naloxone Sublingual Tablets, which are used in drug abuse treatment, Lidocaine transdermal, Apomorphine Injections and it comes in the use for Parkinson’s treatment, Buprenorphine, and indigenous formulations of Fentanyl. Not only this, Nicotine transdermal patches are also made by them for tobacco cessation. Kunal Saxena, who is working in the position of managing director of Rusan Pharma has made a comment that with an investment of about Rs 300 crore in two phases, this new API facility will increase in size their current API-making capacity from 40 metric tonnes in Ankleshwar to 400 metric tonnes in Pithampur. Scroll down the page to learn more information about the news.

Furthermore, The statement from the company came out that the current GMP permit for its APIs ended formulations provision has the capacity to meet 90 percent of the global demand. The company has the approval of several authorities for example The South African Health Products Regulatory Authority, Health Canada, the European Union, the United Arab Emirates, and the Therapeutic Goods Administration of Australia. If we get any further details we will tell you first at the same site. Stay tuned with us for more updates.

Rashmi Mathur

Rashmi Mathur has 11 years experience in the entertainment industry and has excelled throughout her professional life.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button